



Science For A Better Life

HNE chemical probe

BAY-678

F. von Nussbaum, V. Li

August 6th 2015



Human Neutrophil Elastase, HNE (EC 3.4.21.37)


A Key Player in Inflammation (1/3)

Structure

- Ser protease (His-Asp-Ser)
- chymotrypsin family

Function

- broad substrate specificity
- Val-|-Xaa & Ala-|-Xaa



Classical Ser protease



Human Neutrophil Elastase, HNE (EC 3.4.21.37)

A Key Player in Inflammation (2/3)

Structure


- Ser protease (His-Asp-Ser)
- chymotrypsin family

Function

- broad substrate specificity
- Val-|-Xaa & Ala-|-Xaa

Pharmacology

- inflammation (ECM**) & signaling
- host defense (bacteria)



Highly active enzyme ...

*adapted from <http://ckcsphysiology.wikispaces.com/>

**extracellular matrix



Human Neutrophil Elastase, HNE (EC 3.4.21.37)

A Key Player in Inflammation (3/3)

Structure

- Ser protease (His-Asp-Ser)
- chymotrypsin family

Function


- broad substrate specificity
- Val-|-Xaa & Ala-|-Xaa

Pharmacology

- inflammation (ECM**) & signaling
- host defense (bacteria)

Regulation

- by compartmentation
- by anti-proteases (α 1PI***)



Highly active enzyme that has to be regulated strictly

*adapted from <http://ckcsphysiology.wikispaces.com/>


extracellular matrix * α -1-proteinase inhibitor

Bayer HealthCare



Elastase in Inflammation and Autoimmunity

The Elastase – Anti-Protease Balance is Disturbed




Exciting target for ULTRA-DD collaboration



History of HNE Inhibitors: Biologicals

Selection of Inhibitors



$K_i < 0.1$ nM
i.v.

Human alpha-1 protease inhibitor (AATD)

Prolastin®


Talecris, 1987

Zemaira®

CSL Behring, 2003

Aralast®

Baxter, 2003



K_i 0.08 nM
i.v.

tiprelstat

Rec. human elafin (Ph 2 postoperative inflam. complication)

Elafin

Proteo Biotec, ongoing

➔ *Loss of activity under oxidative stress conditions*

➔ *Alpha-1 protease inhibitor: no inhibition of membrane bound HNE*




History of HNE Inhibitors: First SMOLs*


Suicide Inhibitors (a Selection of Inhibitors)

Mode-of-action: mechanism-based (covalent / reactive inhibitors)

multiple pharmacophores of electrophilic ketons, acylators, and transition state analogs



Elaspol[®] (ALI/SIRS, only Japan & South Korea)
Ono, 2002 & 2006



ONO 6818 (Ph1/2 COPD)
Ono, discontinued 2002


→ **Metabolic liabilities**
→ **Prone to adverse effects**



History of HNE Inhibitors: recent SMOLs

Reversible, Non-reactive Inhibitors (e.g. BAY-678)

Chemical Probe
BAY-678




- *Specific & selective*
- *Oral bioavailable*
- *Well tolerated & safe*



Characterization of Chemical Probe BAY-678


Potency

see also von Nussbaum F, Li V *et al. ChemMedChem* 2015



BAY-678

IC ₅₀ humanNE	20 nM (<i>R</i>) 60 nM (rac.); <u>> 2,000 nM (<i>S</i>)</u>
K _i humanNE	15 nM




High potency for a non-reactive, reversible protease inhibitor
(*S*)-enantiomer of BAY-678 is inactive (negative control)



Characterization of Chemical Probe BAY-678

Selectivity

see also von Nussbaum F, Li V *et al. ChemMedChem* 2015



BAY-678

K_i humanNE (HNE)

15 nM

K_i ratNE (RNE)

600 nM

K_i murineNE (MNE)

700 nM

Serine Protease	IC ₅₀ [μM]	Serine Protease	IC ₅₀ [μM]
Pancreas elastase	> 30	Kallikrein-B1	> 30
Cathepsin G	> 30	Kallikrein-1	> 30
Chymotrypsin	> 30	Kallikrein-4	> 30
Trypsin	> 30	Kallikrein-5	> 30
Chymase	> 30	Kallikrein-7	> 30
DPPII	> 30	Kallikrein-12	> 30
DPPIV	> 30	FAP	> 30
Urokinase	> 30	FVIIa	> 30
Thrombin	> 30	FIXa	> 30
FXa	> 30	FXIa	> 30
Plasmin	> 30		


Very high selectivity (>2,000 fold) versus similar serine proteases
Lower potency versus rodent neutrophil elastases



Characterization of Chemical Probe BAY-678

Specificity (1/2) [See also Backup Slides]

see also von Nussbaum F, Li V *et al. ChemMedChem* 2015



BAY-678

K_i humanNE

15 nM

LeadProfilingScreen
@ MDS Pharma Services, Taiwan

Radioligand Binding Assays with 10 μ M BAY-678:

Panel of **64 pharmacological relevant targets**
(e.g. receptors & transporter)


PASSED

No significant effects against numerous pharmaceutical relevant targets



Characterization of Chemical Probe BAY-678

Specificity (2/2)



BAY-678

K_i humanNE

15 nM

Kinase Panel (in house)

Functional Kinase Activity with 20 μ M* BAY-678:

Initial panel of **7 kinases**

(incl. 4 tyrosine & 3 serine/threonine kinases)

PASSED


* dose response, highest concentration used: 20 μ M

No significant effects against prominent kinase target class

Investigating the Binding Mode (X-Ray)

HNE Complex with Close Congener of BAY-678

see also Hansen *et al.* *J. Mol. Biol.* 2011







Induced-Fit Binding Mode (X-Ray)

S2 Pocket Widens for Cyanophenyl Residue

see also Hansen *et al. J. Mol. Biol.* 2011




Significantly smaller S2 pocket in apo structure



Induced-Fit Binding Mode (X-Ray)

BAY-678

see also von Nussbaum F, Li V *et al.* *ChemMedChem* 2015



Crystal structure of HNE in complex with BAY-678: The protease is shown in a stick representation (white) with transparent Connolly-like surface; ligand 20 (purple) is shown as balls and sticks. Heteroatoms are colored as follows: oxygen, red; nitrogen, blue; fluorine, cyan.


RCSB Protein Data Bank (PDB) access code **5a0a**



Characterization of Chemical Probe BAY-678

Pharmacokinetics

see also von Nussbaum F, Li V *et al. ChemMedChem* 2015




BAY-678

PK rat i.v.	$t_{1/2}$ 1.3 h, CL_{matrix} 2.0 L/h*kg, AUC_{norm} 0.50 kg*h/L, V_{ss} 3.9 L/kg
PK rat p.o.	$t_{1/2}$ 1.3 h, AUC_{norm} 0.42 kg*h/L, BA 83%
CYP inhib.	CYP 2C9 12 μ M; other > 50 μ M
F_U rat	~30%
Caco-2 cellperm.	$P_{app,A-B}$ 228 nm/s, $P_{app,B-A}$ 606 nm/s, $Efflux_{ratio}$ 2.7

Pharmacokinetics in Rats

BAY-678 plasma concentration versus time




BAY-678 is cell permeable and reveals an overall good pharmacokinetics



Targeting Elastase in More Complex Settings

Model of the Kinetics of Free Extra-cellular Elastase, the Potential Driver of Inflammation and Autoimmunity



It's all about concentration & timing



Investigating BAY-678 in More Complex Settings

Beyond the Interaction with the Isolated Target

Investigating cellular action of elastase (not meaningful)

No interference with intra-cellular elastase activity (host defense) expected as this would request a very high concentration of the inhibitor (target concentration in cells is millimolar!)

Investigating extra-cellular action of elastase

Efficacy of inhibitor treatment is assessed in *in vivo* models with out-of-balance elastase activity driving presumably the onset and progression of the disease

→ *In vivo / ex vivo efficacy assessment of BAY-678*



In vivo / ex vivo Efficacy Assessment of BAY-678

Per oral Administration of Inhibitor (1/2)

Efficacy demonstrated in acute *in vivo* models

- Protease-induced acute lung injury (ALI) in mice
(lung hemorrhage, neutrophil count in lung lavage)
- Thread infarct model in rats
(infarct size, cardiac function)



Neutrophilic
Inflammation

} details on slides #20/21

Efficacy demonstrated in sub-chronic *in vivo* models

- Cigarette smoke-induced lung injury in guinea pigs
(inflammatory cell count in lung lavage)

→ ***Anti-inflammatory mode-of-action of BAY-678***




In vivo / ex vivo Efficacy Assessment of BAY-678

Per oral Administration of Inhibitor (2/2)

Efficacy demonstrated in chronic *in vivo* models

- Protease-induced lung emphysema in mice
(lung compliance and alveolar morphometry)
- Hypoxia-induced pulmonary arterial hypertension (PAH) in mice and rats
(heart hemodynamics & hypertrophy, biomarker, pulmonary artery muscularisation)
- Monocrotaline (MCT)-induced PAH in rats
(heart hemodynamics & hypertrophy, biomarker)



} details on back-up slides


Anti-remodeling mode-of-action of BAY-678



BAY-678 in Protease-induced ALI Mice Models

Scheme of HNE-induced and PPE*-induced ALI Scenario

see also von Nussbaum F, Li V *et al. Chem. Med. Chem.* 2015




* porcine pancreas elastase




BAY-678 in Protease-induced ALI Mice Models

Lung Hemorrhage Data

see also von Nussbaum F, Li V *et al. Chem. Med. Chem.* 2015



*Hitting the (exogenous) HNE target
in the lung after oral administration*



*Reduction of (endogenous)
MNE driven lung inflammation*


* biochemical in vitro assay

Bayer HealthCare



Human Neutrophil Elastase Inhibitor Probe

Summary



BAY-678 fulfills all SGC chemical probe criteria.

We consider BAY-678 as an attractive & novel SGC probe for HNE



HNE Inhibitor Programs

Acknowledgements

Adrian Tersteegen

Armin Kern

Barbara-Albrecht

Christopher Kallus

Dagmar Karthaus

Daniel Meibom

Dieter Lang

Dirk Meurer

Dirk Schneider

Frank Kramer

Franz von Nussbaum

Günter Benz

Herbert Himmel

Heike Gielen-Härtwig

Holger Paulsen

Hubert Trübel

Ines Bohlinger

Jens Ergüden

Jens Schamberger

Joachim Mittendorf

Jörg Keldenich

Johannes Nagelschmitz

Julia Freundlieb

Karl-Heinz Schlemmer

Katja Zimmermann

Kevin Nash

Klemens Lustig

Lars Bärfacker

Leila Telan

Martin Radtke

Martina Delbeck

Martina Schäfer

Mary Fitzgerald

Michael Gerisch

Michael Hoffmann

Raimund Kast

Rolf Grosser

Rolf Henning

Sina Micus

Sonja Anlauf

Stefan Golz

Stefan Schäfer

Susanne Wegener

Swen Allerheiligen

Thomas Kuhlmann

Ullrich Rosentreter

Ursula Krenz

Uwe Münster

Volker Geiss

Volkhart Li

Walter Kroh



Science For A Better Life

Thank you!